LEWIS, K.; PERIS, K.; SEKULIC, A.; STRATIGOS, A.; DUNN, L.; EROGLU, Z.; CHANG, A. L.; MIGDEN, M.; LI, S.; YOO, S.-Y.; MOHAN, K.; COATES, E.; OKOYE, E.; BAURAIN, J.-F.; BECHTER, O.; HAUSCHILD, A.; BUTLER, M.; HERNANDEZ-AYA, L.; LICITRA, L.; NEVES, R.; RUIZ, E.; SEEBACH, F.; LOWY, I.; BOWLER, T.; FURY, M. Interim Analysis of Phase 2 Results for Cemiplimab in Patients with Metastatic Basal Cell Carcinoma (mBCC) who Progressed on or are Intolerant to Hedgehog Inhibitors (HHIs). SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 1, p. s3, 2021. DOI: 10.25251/skin.5.supp.3. Disponível em: https://jofskin.org/33014/index.php/skin/article/view/1155. Acesso em: 4 jul. 2024.